Moreover, in view of the increased level of apoptosis in circulating DCs in patients with cancer described here, it is tempting to speculate that pro-apoptotic tumor products that regularly gain access to the peripheral circulation at high concentrations, such as IL-10 and gangliosides [30,31], could potentially impair viability of blood DCs in vivo [2]. This evidence concerns the gene IL10 and cancer.